Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aquestive Therapeutics, Inc.

< Previous 1 2 Next >
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST EBS GMDA
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Completes $45 Million Debt Refinancing
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.